P E Breukhoven1, G F Kerkhof, M van Dijk, A C S Hokken-Koelega. 1. Department of Paediatrics, Subdivision of Endocrinology, Erasmus University Medical Center/Sophia Children's Hospital, 3015 GJ Rotterdam, The Netherlands. p.breukhoven@erasmusmc.nl
Abstract
CONTEXT: GH treatment of short children born small for gestational age (SGA) results in a decline in fat mass (FM) and an increase in lean body mass (LBM). It is, however, unknown whether these changes persist into adulthood. OBJECTIVE: Our objective was to assess the long-term impact of GH treatment during childhood on body composition and fat distribution. PATIENTS AND DESIGN: A total of 377 young adults participated in this cross-sectional study: 59 previously GH-treated young SGA adults compared to 52 untreated SGA adults with short stature (SGA-S), 161 SGA adults with spontaneous catch-up growth (SGA-CU), and 105 healthy normal-statured controls born appropriate for gestational age (AGA). OUTCOME MEASURES: Body composition and fat distribution were determined by dual-energy x-ray absorptiometry. RESULTS: Mean (SD) duration of GH treatment was 7.7 (2.4) yr and period after discontinuation 6.8 (1.8) yr. FM, fat distribution, and LBM of GH-treated SGA adults were not significantly different from that of untreated SGA-S adults. GH-treated SGA adults also had a similar FM and fat distribution as SGA-CU adults but a lower LBM. All SGA subgroups had a lower LBM and tended to have a higher FM than healthy AGA controls. CONCLUSION: Body composition and fat distribution of previously GH-treated SGA adults was similar to that of untreated SGA-S adults. GH-induced catch-up growth has no unfavorable effect on FM and fat distribution compared with spontaneous catch-up growth. However, our study shows that SGA adults in general may have a different body composition than healthy AGA controls.
CONTEXT: GH treatment of short children born small for gestational age (SGA) results in a decline in fat mass (FM) and an increase in lean body mass (LBM). It is, however, unknown whether these changes persist into adulthood. OBJECTIVE: Our objective was to assess the long-term impact of GH treatment during childhood on body composition and fat distribution. PATIENTS AND DESIGN: A total of 377 young adults participated in this cross-sectional study: 59 previously GH-treated young SGA adults compared to 52 untreated SGA adults with short stature (SGA-S), 161 SGA adults with spontaneous catch-up growth (SGA-CU), and 105 healthy normal-statured controls born appropriate for gestational age (AGA). OUTCOME MEASURES: Body composition and fat distribution were determined by dual-energy x-ray absorptiometry. RESULTS: Mean (SD) duration of GH treatment was 7.7 (2.4) yr and period after discontinuation 6.8 (1.8) yr. FM, fat distribution, and LBM of GH-treated SGA adults were not significantly different from that of untreated SGA-S adults. GH-treated SGA adults also had a similar FM and fat distribution as SGA-CU adults but a lower LBM. All SGA subgroups had a lower LBM and tended to have a higher FM than healthy AGA controls. CONCLUSION: Body composition and fat distribution of previously GH-treated SGA adults was similar to that of untreated SGA-S adults. GH-induced catch-up growth has no unfavorable effect on FM and fat distribution compared with spontaneous catch-up growth. However, our study shows that SGA adults in general may have a different body composition than healthy AGA controls.
Authors: Carolina C J Smeets; Veryan Codd; Matthew Denniff; Nilesh J Samani; Anita C S Hokken-Koelega Journal: PLoS One Date: 2017-02-08 Impact factor: 3.240
Authors: Jan M. Wit; Asma Deeb; Bassam Bin-Abbas; Angham Al Mutair; Ekaterina Koledova; Martin O. Savage Journal: J Clin Res Pediatr Endocrinol Date: 2019-07-09
Authors: Stephany H Donze; Veryan Codd; Layla Damen; Wesley J Goedegebuure; Matthew Denniff; Nilesh J Samani; Janiëlle A E M van der Velden; Anita C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2020-06-01 Impact factor: 5.958
Authors: Oluwakemi Lokulo-Sodipe; Eloïse Giabicani; Ana P M Canton; Nawfel Ferrand; Jenny Child; Emma L Wakeling; Gerhard Binder; Irène Netchine; Deborah J G Mackay; Hazel M Inskip; Christopher D Byrne; I Karen Temple; Justin H Davies Journal: Clin Endocrinol (Oxf) Date: 2022-03-21 Impact factor: 3.523
Authors: Ajay Thankamony; Rikke Beck Jensen; Susan M O'Connell; Felix Day; Jeremy Kirk; Malcolm Donaldson; Sten A Ivarsson; Olle Söder; Edna Roche; Hilary Hoey; Ken K Ong; David B Dunger; Anders Juul Journal: J Clin Endocrinol Metab Date: 2015-11-20 Impact factor: 5.958